Par Pharmaceuticals
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$8.1b Valuation: $8.1b | Acquisition | ||
Total Funding | - |
Recent News about Par Pharmaceuticals
EditPar Pharmaceutical, a subsidiary of Endo International, specializes in developing, manufacturing, and marketing generic pharmaceutical products that are safe, innovative, and cost-effective. With over 40 years of experience in the U.S. generic pharmaceutical market, Par Pharmaceutical serves a diverse range of clients, including patients, healthcare providers, and pharmaceutical partners. The company operates in the highly competitive generic pharmaceuticals market, focusing on delivering high-quality medicines that are therapeutic equivalents to brand-name drugs. Par Pharmaceutical's business model revolves around the development and commercialization of generic drugs, contract manufacturing services, and strategic partnerships with innovator companies and brand product marketers. Revenue is generated through the sale of generic pharmaceuticals and contract manufacturing services. The company is committed to improving healthcare by providing uncompromising quality and value through continuous innovation and operational excellence.
Keywords: generic pharmaceuticals, innovation, cost-effective, healthcare, manufacturing, commercialization, partnerships, therapeutic equivalents, U.S. market, quality.